To report a case of Felty syndrome recurrence triggered by immunotherapy in a patient with metastatic melanoma and a history of rheumatoid arthritis, highlighting the clinical significance of this occurrence.
Key Findings:
The patient experienced a significant drop in neutrophil count (ANC 0.0 cells/µL) following immunotherapy, raising concerns for severe complications.
Differential diagnoses included immunotherapy-triggered Felty syndrome and post-viral agranulocytosis, emphasizing the need for careful evaluation.
Prompt initiation of immunosuppressive treatment resulted in rapid recovery of neutrophil counts, demonstrating effective management.
Interpretation:
This case highlights the risk of Felty syndrome recurrence in patients with pre-existing autoimmune conditions undergoing immunotherapy, emphasizing the need for early identification, management, and monitoring.
Limitations:
The case is based on a single patient experience, limiting generalizability.
Potential confounding factors such as concurrent infections and other medications were not fully explored, and long-term follow-up data is lacking.
Conclusion:
Early recognition and collaborative care are crucial in managing patients with autoimmune conditions undergoing immunotherapy to prevent severe complications, underscoring the importance of vigilant monitoring.
